scholarly journals O-22 METABOLIC ASSOCIATED FATTY LIVER DISEASE: A SEVERE LIVER DISEASE

2021 ◽  
Vol 24 ◽  
pp. 100509
Author(s):  
Ana Rafaela S. Do Vale ◽  
Andreza Rosa Cabral ◽  
Naiade S. Almeida ◽  
Antonio Ricardo C.F. Andrade ◽  
Ana Cristina Landim ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Severe Liver ◽  
Severe Liver Disease

scholarly journals Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes

Hepatology ◽  
2008 ◽  
Vol 48 (3) ◽  
pp. 792-798 ◽  
Author(s):  
Anna Ludovica Fracanzani ◽  
Luca Valenti ◽  
Elisabetta Bugianesi ◽  
Marco Andreoletti ◽  
Agostino Colli ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Severe Liver ◽  
Nonalcoholic Fatty Liver ◽  
Severe Liver Disease

scholarly journals Lipid mediators of liver injury in nonalcoholic fatty liver disease

2019 ◽  
Vol 316 (1) ◽  
pp. G75-G81 ◽  
Author(s):  
Suthat Liangpunsakul ◽  
Naga Chalasani
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Cell Injury ◽  
Lipid Mediators ◽  
Severe Liver ◽  
Nonalcoholic Fatty Liver ◽  
Lipid Species ◽  
Severe Liver Disease

Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of histopathological phenotypes ranging from simple steatosis to more severe liver disease associated with cell injury, including nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. Only a subset of patients with NAFLD develop NASH from yet incompletely understood mechanisms. Emerging data suggest lipid species other than triglycerides as contributors to the pathogenesis of NASH. In this mini review, we focus on the recent data on the mechanisms of NASH, focusing on these lipid mediators and their potential as therapeutic targets in NASH.

scholarly journals Biochemical assessment of metabolic associated fatty liver disease

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Armando R. Guerra-Ruiz ◽  
Gregori Casals ◽  
Paula Iruzubieta ◽  
Marta Lalana ◽  
Alba Leis ◽  
...  
Keyword(s):  
At Risk ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Diagnostic Algorithm ◽  
Serological Markers ◽  
Severe Liver ◽  
Number Of Patients ◽  
Patients At Risk ◽  
Severe Liver Disease

Abstract Metabolic-associated fatty liver disease (MAFLD) is defined as fat accumulation in the liver in the presence of metabolic alterations. This disorder is generally asymptomatic and may progress to severe liver disease, which are linked to inflammation and/or fibrosis. MAFLD has a high prevalence (26%) and therefore a considerable number of patients are at high risk of having advanced liver disease. This document provides an overview of the most relevant serological markers in the characterization and diagnosis of MAFLD. An example is provided of a routine diagnostic algorithm that incorporates serological testing. A range of useful serological scores are currently available for the management of MAFLD patients, especially for the stratification of patients at risk of fibrosis. A large proportion of the population is at risk of developing severe liver disease. The integration of non-invasive serological markers in the stratification of patients at risk for liver fibrosis may contribute to improve the control and management of MAFLD patients.

scholarly journals Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease

2016 ◽  
Vol 45 (4) ◽  
pp. 510-518 ◽  
Author(s):  
S. Petta ◽  
S. Ciminnisi ◽  
V. Di Marco ◽  
D. Cabibi ◽  
C. Cammà ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Severe Liver ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document